19:21 , Nov 15, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers; other

TECHNOLOGY: Serum markers; computational models A computational model based on mucosal-associated invariant T cell expression of CCR6, CD56, CD25 and PD-1 in blood could help diagnose Type I diabetes. In peripheral blood samples from adult...
23:52 , Feb 24, 2017 |  BC Extra  |  Clinical News

A T-cell gene signature in infants could predict Type I diabetes

German researchers published a gene signature found in T cells from six month old infants that preceded the development of β cell autoantibodies in those at high risk for Type I diabetes. The paper was...
07:00 , Aug 11, 2011 |  BC Innovations  |  Targets & Mechanisms

Gutsy call on Th17 cells

Researchers at the Yale School of Medicine have shown that the small intestine regulates proinflammatory T helper type 17 cells via two mechanisms, including one that leads to an immunosuppressive, regulatory phenotype. 1 The findings...
07:00 , Aug 4, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Autoimmune disease Autoimmune; multiple sclerosis (MS) CD3; CC chemokine receptor 6 (CCR6; CD196); chemokine CC motif ligand 20 (CCL20; MIP3A) Mouse studies suggest promoting T...
07:00 , May 13, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Autoimmune disease Rheumatoid arthritis (RA) CC chemokine receptor 6 (CCR6; CD196); IL-17 A genomewide association study identified a SNP in CCR6 that could help predict...
07:00 , Jul 23, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Psoriasis Chemokine receptor 6 (CCR6; CD196) Studies in mice suggest that inhibiting CCR6 may help treat psoriasis. In Ccr6-deficient mice, interleukin-23 (IL-23)-induced dermal inflammation...
07:00 , Apr 16, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Multiple sclerosis (MS) CC chemokine receptor 6 (CCR6) A study in mice suggests that antagonizing CCR6 could help prevent MS....
07:00 , Mar 19, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Autoimmune disease Crohn's disease CD161 In vitro studies suggest that targeting CD161 could help treat Crohn's disease. In cells isolated from...
08:00 , Dec 11, 2008 |  BC Innovations  |  Distillery Therapeutics

This week in therapeutics

The Distillery: Therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Inflammatory bowel disease (IBD) Nucleotide-binding oligomerization domain containing 1 (NOD1; CARD4); chemokine (CC motif) receptor 6 (CCR6) Studies in mice suggest...